Dxcover is an ambitious mission-led business that has developed a way of detecting cancer at an early stage using a simple to undertake blood test. Its mission is to be a world leader in liquid biopsy and artificial intelligence for the early detection of cancers and other diseases.
Dxcover spun out from the University of Strathclyde in 2019 as ClinSpec Diagnostics Limited and rebranded as Dxcover Limited in 2021, by which point it had secured £5.1m of funding. In August 2020, SIS Ventures invested in a funding round led by Mercia’s EIS Funds, and co-invested alongside Eos Advisory, Scottish Enterprise and the University of Strathclyde.
Dxcover’s technology is based on the world leading research of Matthew J Baker PhD and has the potential to revolutionise cancer diagnostics. The Dxcover platform combines novel hardware with artificial intelligence algorithms to analyse a patient’s blood and detect the presence or absence of disease.
The test is fast, high-throughput and inexpensive. Enabling the earlier diagnosis of cancer, Dxcover’s technology will result in significantly higher patient survival rates compared to late-stage diagnosis, increasing the availability of treatment options and improving chances of recovery and a better quality of life.
Dxcover has successfully completed two groundbreaking studies on earlier diagnosis of brain cancer and is currently developing the platform for the detection of commonly occurring cancers.
Medical device specialist Nebu~Flow secures £1.7m investmentRead more about Medical device specialist Nebu~Flow secures £1.7m investment
Carcinotech secures £1.6m of new investment from leading Scottish investorsRead more about Carcinotech secures £1.6m of new investment from leading Scottish investors
Good-Loop accelerates US expansion plans after closing $6.1M Series A roundRead more about Good-Loop accelerates US expansion plans after closing $6.1M Series A round